Quoting Anand Patel, an Assistant Professor and the Director of Inpatient Leukemia Service at the UChicago Medicine, on Twitter:
“It was a pleasure speaking about accelerated/blast-phase MPNs at the Video Journal of Hematological Oncology IWAL meeting – much work needs to be done to move the needle for our patients. IDH inhibition +/- JAK inhibitor may be a promising option for those w/ IDH mutations!”
Source: Anand Patel/Twitter
